Kriya Therapeutics: Funding, Investors & Team (Oct 2026)
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. Kriya targets conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues. Kriya's team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. Kriya uses algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases.
Kriya Therapeutics has raised $914M across 5 funding rounds on record, the most recent a Series C of $313M announced in Aug 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kriya Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2025.
Kriya Therapeutics Funding Rounds
Kriya Therapeutics raised $80.5M in an undisclosed round announced in May 2020.
1.2 years later, a Series B of $100M was announced in Jul 2021.
10 months later, a Series C of $270M was announced in May 2022.
1.2 years later, a Series C of $150M was announced in Jul 2023.
2.1 years later, a Series C of $313M was announced in Aug 2025.
Kriya Therapeutics Founders and Leadership Team
Contact details for the Kriya Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Kriya Therapeutics Funding Compared to Other Biotechnology Startups
Kriya Therapeutics' latest round of $313M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kriya Therapeutics in Biotechnology and Redwood City
Companies Similar to Kriya Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Kriya Therapeutics Funding FAQs
What does Kriya Therapeutics do?
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. Kriya targets conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate human tissues. Kriya's team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. Kriya uses algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases.
How much funding has Kriya Therapeutics raised?
Kriya Therapeutics has raised $914M across 5 rounds on record. The most recent is a Series C of $313M announced in Aug 2025.
When did Kriya Therapeutics last raise funding?
Kriya Therapeutics' most recent funding round on record is a Series C of $313M, announced in Aug 2025.
Who is the CEO of Kriya Therapeutics?
Shankar Ramaswamy is listed as CEO at Kriya Therapeutics.
Where is Kriya Therapeutics headquartered?
Kriya Therapeutics is based in Redwood City, California, United States.
How many employees does Kriya Therapeutics have?
Kriya Therapeutics is in the 101-250 employee band.
How does Kriya Therapeutics' funding compare to other Biotechnology startups?
Kriya Therapeutics' latest round of $313M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Kriya Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kriya Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.